Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Joins Companies Posting Certain Payments to Physicians

This article was originally published in The Pink Sheet Daily

Executive Summary

But Vermont law and pending federal legislation would require disclosure of far more data.

You may also be interested in...



Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More

The most highly paid Lilly outside physician consultant in the first quarter of 2009 - San Jose, Calif., psychiatrist Manoj Waikar ($70,050) - says he was convinced that the public listing of financial ties was a good idea when his patients said they approved of his work with pharmaceutical companies

Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More

The most highly paid Lilly outside physician consultant in the first quarter of 2009 - San Jose, Calif., psychiatrist Manoj Waikar ($70,050) - says he was convinced that the public listing of financial ties was a good idea when his patients said they approved of his work with pharmaceutical companies

Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences

Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel